Linda Lebon
Consejero General en OSE IMMUNOTHERAPEUTICS .
Cargos activos de Linda Lebon
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
OSE IMMUNOTHERAPEUTICS | Consejero General | 20/12/2021 | - |
Historial de carrera de Linda Lebon
Antiguos cargos conocidos de Linda Lebon.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
BIOSENIC SA | Consejero General | 29/10/2018 | 01/09/2021 |
ARGENX SE | Consejero General | - | - |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Consejero General | - | - |
Formación de Linda Lebon.
École des Hautes Études Commerciales de Paris | Masters Business Admin |
Centre Hospitalier Universitaire de Liege | Graduate Degree |
Estadísticas
Internacional
Bélgica | 4 |
Francia | 3 |
Países Bajos | 2 |
Operativa
General Counsel | 4 |
Masters Business Admin | 1 |
Graduate Degree | 1 |
Sectorial
Health Technology | 5 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
ARGENX SE | Health Technology |
OSE IMMUNOTHERAPEUTICS | Health Technology |
Empresas privadas | 2 |
---|---|
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Health Technology |
Bone Therapeutics SA
Bone Therapeutics SA Pharmaceuticals: MajorHealth Technology Bone Therapeutics SA is a cell therapy company, which engages in the regenerative therapy addressing for unmet medical needs in the field of bone diseases and orthopedics. Its products include Allob and JTA-004. The company was founded by Jacques Reymann on June 16, 2006 and is headquartered in Gosselies, Belgium. | Health Technology |
- Bolsa de valores
- Insiders
- Linda Lebon
- Experiencia